Avid Bioservices Inc (CDMO)

[JJ1223]

Spin again. To be clear they will contract a third party agency to determine value of the IP and then deal it. Very simple to understand.

What spin bfiest?? The words I posted are a direct quote from Mr. White The way I see it, we have two options to our investment in Peregrine.
Option One- We know the current BOD has issues from a lack of transparent communication, failure to date to gain FDA approval or partnership on Bavi or Exosomes, and the salaries taken during this period of little progress. What we do know is that they work through world class institutions and Doctors with the aim of perfecting the approach(s) that may unlock the pathway to success. Getting a drug through this process is long and expensive. Phosphatidylserine research is everywhere, with new abstracts weekly. Dr Wolchok and others have been very positive on the results observed in their preclinical studies, and actual studies in different Phase trials are under way. They have built Avid into an award winning cGMP facility that provides nice growth and profits to help off set the costs of clinical development. All actions seem to be working toward a goal as many I/O drugs have suffered from toxicity issues and late stage trial failures Car-t issues of toxic side effects have been aided by the inclusion of Bavi...according to Dr Wolchok in various presentations and lectures. Due to costs, the company has not yet touched any viral opportunities.
Option Two- Ronin takes over and continues to expand on the growth of Avid, but states the will sell both Bavi and Exosomes platforms, and allow another company to develop and profit from the vast potential both programs may offer. That to me is a huge risk, as shareholders will get their $5-$10 per share on the sale, but will not be part of the massive growth of potential when either or both reach the market.

After all these years, why would any investor give up if we could potentially be on the doorstep to success? Peregrine is not running clinical trials, and the restructure should make profitability a reality in the near term. The BOD needs to change and salaries adjusted, but to give in at this point is a vote for Ronin. The vote will be either for the reason you invested in
Peregrine and the reason you remain here. At some point in time, some company will cash in on PS Targeting and the Exosome diagnostic platform IMO. A vote for Ronin says that company will not be Peregrine. Ronin told you everything you wanted to hear to
get your vote. Options are never as good nor as bad as they seem on the surface.